Skip to main content

Systemic Scleroderma clinical trials at UCSF
1 research study open to eligible people

  • Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

    open to eligible people ages 18 years and up

    A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).

    San Francisco, California and other locations

Last updated: